title: Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.
abstract: Our aim was to determine if fluorodeoxyglucose positron emission tomography (FDG-PET) could be correlated with a pathological response in patients with esophageal adenocarcinoma receiving neoadjuvant chemotherapy and/or chemoradiation therapy. Patients with resectable, histologically proven adenocarcinoma of the esophagus were entered in the study. Preoperative chemotherapy comprised two cycles of cisplatin and 5-fluorouracil. Radiation therapy commenced with the second cycle on day 22. FDG-PET images were obtained pre-treatment and on completion of intended neo-adjuvant treatment. Quantification was achieved by the calculation of both standardized uptake values (SUV) and tumor/liver ratios (TLR). Evidence of histopathological response was identified according to the Mandard tumor regression scoring system. There were 45 patients, 22 receiving neoadjuvant chemotherapy and 23 chemoradiation therapy. Forty patients underwent surgical resection. Seven patients (16%) had a histopathological response. The mean percentage change in SUV in the histological responders group was -56.8% (SD 29) and in the non-responders -27.8% (SD 32.1) (P = 0.035). The mean percentage change in TLR was -49.1% (SD 44.8) in the responders and in the non-responders -27.3% (SD 31.3) (P = 0.128). There was no difference between the two methods of assessment, however there was less variation with SUV. There was no correlation between the FDG-PET response and the histopathological response. Presently an FDG-PET scan performed 3-6 weeks after neoadjuvant therapy for adenocarcinoma of the esophagus should not be used as a marker of the potential result of the treatment. The optimal timing of a second FDG-PET remains unclear.
authors.affiliation: Department of Surgery, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia. m.smithers@.uq.edu.au
authors.forename: B M
authors.initials: BM
authors.lastname: Smithers
authors.forename: G C
authors.initials: GC
authors.lastname: Couper
authors.forename: J M
authors.initials: JM
authors.lastname: Thomas
authors.forename: D
authors.initials: D
authors.lastname: Wong
authors.forename: D C
authors.initials: DC
authors.lastname: Gotley
authors.forename: I
authors.initials: I
authors.lastname: Martin
authors.forename: J A
authors.initials: JA
authors.lastname: Harvey
authors.forename: D B
authors.initials: DB
authors.lastname: Thomson
authors.forename: E T
authors.initials: ET
authors.lastname: Walpole
authors.forename: N
authors.initials: N
authors.lastname: Watts
authors.forename: B H
authors.initials: BH
authors.lastname: Burmeister
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000628:therapy*; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D020360:Neoadjuvant Therapy; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18